Notice of Proposals To Engage in Permissible Nonbanking Activities or To Acquire Companies That Are Engaged in Permissible Nonbanking Activities, 77877 [2010-31241]
Download as PDF
<![CDATA[
Federal Register / Vol. 75, No. 239 / Tuesday, December 14, 2010 / Notices
disability, please contact Penelope
Beattie on 202–452–3982. For the
hearing impaired only, please use the
Telecommunication Device for the Deaf
(TDD) on 202–263–4869.
Privacy Act Notice: Providing the
information requested is voluntary;
however, failure to provide your name,
date of birth, and social security number
or passport number may result in denial
of entry to the Federal Reserve Board.
This information is solicited pursuant to
Sections 10 and 11 of the Federal
Reserve Act and will be used to
facilitate a search of law enforcement
databases to confirm that no threat is
posed to Board employees or property.
It may be disclosed to other persons to
evaluate a potential threat. The
information also may be provided to law
enforcement agencies, courts and others,
but only to the extent necessary to
investigate or prosecute a violation of
law.
MATTERS TO BE CONSIDERED:
Discussion Agenda
1. Proposed Rule Governing Debit
Card Interchange Fees and Routing.
Note: 1. The staff memo to the Board will
be made available to the public in paper and
the background material will be made
available on a computer disc in Word format.
If you require a paper copy of the document,
please call Penelope Beattie on 202–452–
3982.
2. This meeting will be recorded for
the benefit of those unable to attend.
Computer discs (CDs) will then be
available for listening in the Board’s
Freedom of Information Office, and
copies can be ordered for $4 per disc by
calling 202–452–3684 or by writing to:
Freedom of Information Office, Board of
Governors of the Federal Reserve
System, Washington, DC 20551.
FOR MORE INFORMATION PLEASE CONTACT:
Michelle Smith, Director, or Dave
Skidmore, Assistant to the Board, Office
of Board Members at 202–452–2955.
You may
call 202–452–3206 for a recorded
announcement of this meeting; or you
may contact the Board’s Web site at
https://www.federalreserve.gov for an
electronic announcement. (The Web
page also includes procedural and other
information about the open meeting.)
srobinson on DSKHWCL6B1PROD with NOTICES
SUPPLEMENTARY INFORMATION:
FEDERAL RESERVE SYSTEM
Notice of Proposals To Engage in
Permissible Nonbanking Activities or
To Acquire Companies That Are
Engaged in Permissible Nonbanking
Activities
The companies listed in this notice
have given notice under section 4 of the
Bank Holding Company Act (12 U.S.C.
1843) (BHC Act) and Regulation Y, (12
CFR part 225) to engage de novo, or to
acquire or control voting securities or
assets of a company, including the
companies listed below, that engages
either directly or through a subsidiary or
other company, in a nonbanking activity
that is listed in § 225.28 of Regulation Y
(12 CFR 225.28) or that the Board has
determined by Order to be closely
related to banking and permissible for
bank holding companies. Unless
otherwise noted, these activities will be
conducted throughout the United States.
Each notice is available for inspection
at the Federal Reserve Bank indicated.
The notice also will be available for
inspection at the offices of the Board of
Governors. Interested persons may
express their views in writing on the
question whether the proposal complies
with the standards of section 4 of the
BHC Act.
Unless otherwise noted, comments
regarding the applications must be
received at the Reserve Bank indicated
or the offices of the Board of Governors
not later than December 28, 2010.
A. Federal Reserve Bank of
Minneapolis (Jacqueline G. King,
Community Affairs Officer) 90
Hennepin Avenue, Minneapolis,
Minnesota 55480–0291:
1. Bigfork Bancshares, Inc., Bigfork,
Minnesota; to engage, de novo, in
extending credit and servicing loans,
pursuant to section 225.28(b)(1) of
Regulation Y.
Board of Governors of the Federal Reserve
System, December 8, 2010.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. 2010–31241 Filed 12–13–10; 8:45 am]
BILLING CODE 6210–01–P
Dated: December 9, 2010.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. 2010–31410 Filed 12–10–10; 11:15 am]
BILLING CODE 6210–01–P
VerDate Mar<15>2010
17:09 Dec 13, 2010
Jkt 223001
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
77877
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket Nos. FDA–2010–E–0022; FDA–
2010–E–0023; FDA–2010–E–0024]
Determination of Regulatory Review
Period for Purposes of Patent
Extension; VIBATIV
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) has determined
the regulatory review period for
VIBATIV and is publishing this notice
of that determination as required by
law. FDA has made the determination
because of the submission of
applications to the Director of Patents
and Trademarks, Department of
Commerce, for the extension of patents
which claim that human drug product.
ADDRESSES: Submit electronic
comments to https://
www.regulations.gov. Submit written
petitions along with three copies and
written comments to the Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Beverly Friedman, Office of Regulatory
Policy, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 51,
rm. 6222, Silver Spring, MD 20993–
0002, 301–796–3602.
SUPPLEMENTARY INFORMATION: The Drug
Price Competition and Patent Term
Restoration Act of 1984 (Pub. L. 98–417)
and the Generic Animal Drug and Patent
Term Restoration Act (Pub. L. 100–670)
generally provide that a patent may be
extended for a period of up to 5 years
so long as the patented item (human
drug product, animal drug product,
medical device, food additive, or color
additive) was subject to regulatory
review by FDA before the item was
marketed. Under these acts, a product’s
regulatory review period forms the basis
for determining the amount of extension
an applicant may receive.
A regulatory review period consists of
two periods of time: A testing phase and
an approval phase. For human drug
products, the testing phase begins when
the exemption to permit the clinical
investigations of the drug becomes
effective and runs until the approval
phase begins. The approval phase starts
with the initial submission of an
application to market the human drug
product and continues until FDA grants
permission to market the drug product.
SUMMARY:
E:\FR\FM\14DEN1.SGM
14DEN1
]]>Agencies
[Federal Register Volume 75, Number 239 (Tuesday, December 14, 2010)]
[Notices]
[Page 77877]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-31241]
-----------------------------------------------------------------------
FEDERAL RESERVE SYSTEM
Notice of Proposals To Engage in Permissible Nonbanking
Activities or To Acquire Companies That Are Engaged in Permissible
Nonbanking Activities
The companies listed in this notice have given notice under section
4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and
Regulation Y, (12 CFR part 225) to engage de novo, or to acquire or
control voting securities or assets of a company, including the
companies listed below, that engages either directly or through a
subsidiary or other company, in a nonbanking activity that is listed in
Sec. 225.28 of Regulation Y (12 CFR 225.28) or that the Board has
determined by Order to be closely related to banking and permissible
for bank holding companies. Unless otherwise noted, these activities
will be conducted throughout the United States.
Each notice is available for inspection at the Federal Reserve Bank
indicated. The notice also will be available for inspection at the
offices of the Board of Governors. Interested persons may express their
views in writing on the question whether the proposal complies with the
standards of section 4 of the BHC Act.
Unless otherwise noted, comments regarding the applications must be
received at the Reserve Bank indicated or the offices of the Board of
Governors not later than December 28, 2010.
A. Federal Reserve Bank of Minneapolis (Jacqueline G. King,
Community Affairs Officer) 90 Hennepin Avenue, Minneapolis, Minnesota
55480-0291:
1. Bigfork Bancshares, Inc., Bigfork, Minnesota; to engage, de
novo, in extending credit and servicing loans, pursuant to section
225.28(b)(1) of Regulation Y.
Board of Governors of the Federal Reserve System, December 8,
2010.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. 2010-31241 Filed 12-13-10; 8:45 am]
BILLING CODE 6210-01-P
